Yash Patel, MD
Internal Medicine · Parsons, KSNPI 1205284601
Payments from drug & device makers
Across 92 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$309
- Amgen$178
- GSK$162
- Teva Pharmaceuticals USA, Inc.$100
- Lilly USA, LLC$90
- Boehringer Ingelheim$73
- plus $667 from 27 others
What the payments were for
- Food & beverage$1,44892%
- Education$1318%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $309 |
| Amgen | 12 | $178 |
| GSK | 11 | $162 |
| Teva Pharmaceuticals USA, Inc. | 1 | $100 |
| Lilly USA, LLC | 6 | $90 |
| Boehringer Ingelheim | 5 | $73 |
| Corcept Therapeutics | 3 | $56 |
| Abiomed | 1 | $44 |
| Pfizer | 2 | $39 |
| Abbott | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $37 |
| Novartis | 2 | $30 |
| Axsome Therapeutics, Inc. | 2 | $30 |
| Lundbeck LLC | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| AstraZeneca | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $24 |
| Irhythm Technologies, Inc. | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Sanofi | 1 | $20 |
| Bayer | 1 | $20 |
| Biogen | 1 | $20 |
| Si-bone, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Collegium Pharmaceutical, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
How this compares
$1,579 in reported general payments places this provider in the 80th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 119 | $136,576 |
| OzempicSemaglutide | 60 | $73,896 |
| JardianceEmpagliflozin | 78 | $61,202 |
| TrulicityDulaglutide | 30 | $53,336 |
| EliquisApixaban | 48 | $50,537 |
| JanuviaSitagliptin Phosphate | 35 | $30,554 |
| TradjentaLinagliptin | 50 | $27,977 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $24,172 |
| XareltoRivaroxaban | 39 | $23,330 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $19,926 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $16,233 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $14,902 |
| FarxigaDapagliflozin Propanediol | 14 | $14,254 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $14,234 |
| Repatha SureclickEvolocumab | 16 | $13,090 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $90 | $189,913149 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $73 | $98,003144 claims |
| Novo NordiskOzempic, Levemir | $15 | $77,71972 claims |
| PfizerEliquis | $39 | $50,53748 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $162 | $45,62683 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $29 | $33,42167 claims |
| Johnson & JohnsonXarelto | $12 | $23,33039 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $25 | $10,85413 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $24 | $8,08611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Parsons
- Martin KankamLeavenworth$63.4M
- Mark HamblinKansas City$5.2M
- Katherine WillinghamTopeka$4.8M
- Raed Al RajabiWestwood$4.5M
- Leslie SpikesKansas City$4.5M
- Michael CoxTopeka$3.4M
- James RuhlmannHutchinson$2.8M
- Scott TeeterTopeka$1.2M
- Shadi HamdehKansas City$1.1M
- Kyle WorkKansas City$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.